



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C12N 15/86, 15/12, A61K 48/00, C12N 5/10	A2	(11) International Publication Number: WO 99/29883 (43) International Publication Date: 17 June 1999 (17.06.99)
(21) International Application Number: PCT/US98/25575 (22) International Filing Date: 3 December 1998 (03.12.98) (30) Priority Data: 60/067,547 3 December 1997 (03.12.97) US (71) Applicant: THE JOHNS HOPKINS UNIVERSITY [US/US]; Suite 2-100, 2024 E Monument Street, Baltimore, MD 21205 (US). (72) Inventor: DRACHMAN, Daniel, B.; The Johns Hopkins University, Suite 2-100, 2024 E Monument Street, Baltimore, MD 21205 (US). (74) Agents: KAGAN, Sarah, A. et al.; Banner & Witcoff, Ltd., 11th floor, 1001 G Street, N.W., Washington, DC 20001-4597 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: TARGETING ANTIGEN-SPECIFIC T CELLS FOR SPECIFIC IMMUNOTHERAPY OF AUTOIMMUNE DISEASE (57) Abstract Antigen-specific T cells are stimulated to proliferate by activation with properly presented antigen. Targeting a detrimental product to only those cells which are stimulated to proliferate in response to the antigen presentation permits the selective and highly efficient ablation of a key component of the disease symptomology of myasthenia gravis.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

TARGETING ANTIGEN-SPECIFIC T CELLS FOR SPECIFIC IMMUNOTHERAPY OF AUTOIMMUNE DISEASE

This application claims the benefit of provisional application no. 60/067,547 filed December 03, 1997.

5 BACKGROUND OF THE INVENTION

One of the major goals in immunotherapy is to devise methods that will effectively eliminate autoimmune responses in an antigen-specific manner, without otherwise affecting the immune system. Myasthenia gravis (MG), which is perhaps the most thoroughly characterized human autoimmune disease, is characterized clinically by weakness and fatigability of skeletal muscles. The pathogenesis of MG in humans and experimental MG in animals involves an antibody mediated autoimmune response directed against acetylcholine receptors (AChRs) at neuromuscular junctions. Although antibodies are directly responsible for the loss of AChRs at neuromuscular junctions, therapeutic strategies directed at AChR-specific B cells are not practicable in ongoing disease. However, the AChR-antibody response is T cell dependent. Given the pivotal role of CD4+ cells in AChR antibody production, elimination or inactivation of these AChR-specific T cells might abrogate the autoantibody response, with resulting benefit. The key to a specific T cell based therapeutic strategy is to be able to target *sufficient* AChR-specific T cells. However, as in many other autoimmune diseases, the T cell response to the autoantigen in MG is highly heterogeneous. Not only do each individual's T cells respond to multiple epitopes, but there are significant differences in

the patterns of epitopes to which different individuals' T cells respond. Even in rodents inbred to have highly restricted MHC Class II expression, there is significant heterogeneity in the AChR-specific T cell repertoires within a given strain, and even more marked differences in the repertoires in different strains.

5 Thus there is a need in the art for methods to effectively target AChR-specific T cells in patients with myasthenia gravis.

SUMMARY OF THE INVENTION

10 It is an object of the invention to provide methods for activating auto-antigen specific T cells such as AChR-specific T cells in an auto-immune disease patient such as a myasthenia gravis patient.

 It is another object of the invention to provide autologous antigen presenting cells which have been engineered to express, process and present an antigen to activate antigen-specific T cells of a myasthenia gravis patient.

15 It is still another object of the invention to provide a virus for transferring genes to antigen presenting cells so that they express, process, and present an antigen which will stimulate antigen-specific T cells in a myasthenia gravis patient.

 These and other embodiments of the invention are provided by one or more of the embodiments described below. In one embodiment of the invention, a method is provided of activating AChR-specific T cells in a myasthenia gravis patient. Antigen
20 presenting cells (APCs) are removed from a myasthenia gravis patient. The APCs are transduced or transfected with a gene which encodes all or a portion of an acetylcholine receptor (AChR) comprising at least the extracellular domain of the α subunit. The transduced or transfected APCs are reintroduced into the patient, whereby AChR-specific

T cells are activated.

According to yet another aspect of the invention antigen presenting cells of an auto-immune disease patient are provided which are transfected or transduced to express a first segment of DNA encoding all or a portion of AChR comprising its α subunit's extracellular domain. The cells further comprises a second segment of DNA encoding a signal peptide 5' to the first segment, as well as a third segment of DNA encoding a transmembrane and cytoplasmic tail which is 3' to the first segment of DNA. The AChR protein expressed is appropriately processed by endosomes by virtue of the 5' and 3' signals.

Still another aspect of the invention is a virus which infects human APCs. The virus comprises a nucleic acid segment which encodes all or a portion comprising at least an extracellular domain of α -subunit of AchR. It will be readily understood by those of skill in the art that the method is also applicable to other auto-immune diseases, including systemic lupus erythematosus, multiple sclerosis, connective tissue disease, autoimmune pulmonary inflammation, Galliaume Barre Syndrome, autoimmune thyroiditis, insulin-dependent diabetes mellitus (IDDM), graft versus host disease, and rheumatoid arthritis.

The present invention thus provides the art with methods and biological reagents for treating and ameliorating the debilitating effects of myasthenia gravis.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Chimeric gene construct of TACHR with LAMP-1 signal sequence (LAMP-1 sig) and LAMP-1 transmembrane and cytoplasmic domains (LAMP-1Tm/Cyt).
a) Map of construct. The 3 components were amplified by PCR using the primers indicated in Methods, and high-fidelity pfu TACHR α subunit extracellular domain

(TACHR α 1-210) was amplified from plasmid PSS-2, and mouse LAMP-1 sig and tm/cy were amplified from pcDNA1. TACHR α 1-210 was first subcloned into pcDNA3.1' with Hind III at the 5' end, and EcoR I at the 3' end. The mouse LAMP-1 sig was then subcloned 5' to the TACHR α 1-210 with HindIII sites at both the 5' and 3' ends, and the correct orientation was confirmed by PCR, using relevant primers (see text). Finally, the mouse LAMP-1tm/cy domain was cloned 3' to the TACHR α 1-210 with EcoR I and Xho I sites at its 5' and 3' ends respectively. b) RT-PCR detection of chimeric gene mRNA expression. A20 cells were transfected with 50 μ g of the linearized plasmid, and selected with G418 for 10 days. Total RNA was extracted and ssDNA was synthesized. The chimeric gene mRNA was detected by RT-PCR using the 5' TACHR α subunit forward primer and 3' reverse mouse LAMP-1 Tm/Cyt domain primer.

Figure 2. Lymphoproliferation assay, demonstrating stimulation of the AChR-specific T cell line by antigen presenting transfected A20 clones. The mouse TACHR specific T-cell line was prepared as described using TACHR as antigen. Control wild type (WT) A20 B lymphoma cells and transfected A20 clones were irradiated with 15000 rad before being used for antigen presentation. Triplicate microwell cultures were pulsed with 3 H-TdR on day 3, during the last 6 - 12 hrs of culture. Counts from wells containing only APCs were subtracted as background. **Figure 2a)** AChR-specific T cell line proliferation (cpm), using different APCs (splenocytes; WT A20 cells; transfected A20 clones), without or with added TACHR. In this experiment, 2.5×10^4 T cells, and 1×10^3 APCs were added to each well. **Figure 2b)** Dose-response graph, showing the 3 H-TdR incorporation of AChR-specific T cells in response to stimulation by different numbers of transfected A20 cells.

Figure 3 Inhibitory effect of recombinant CTLA4Ig on antigen presentation by transfected A20 cells. Lymphoproliferation assay was set up with 2×10^4 transfected irradiated A20 cells or WT A20 cells as APCs. TACHR was added to some cultures as indicated in Fig.3. Human CTLA4Ig (50 μ g/ml) was added to cultures on day 0 as indicated. [3 H]-TdR was added for the final 6 h of a 4 day culture. Inhibition of proliferation was produced as shown.

Figure 4 Effect of soluble FasL or anti-Fas antibody on proliferation induced by exogenous or endogenous TACHR stimulation. AChR-specific T cells (5×10^4 /well) were incubated with irradiated APCs, either control WT A20 cells or A20 cells stably transfected as above (5×10^4 /well). AChR (2.5 μ g/ml) was added to some of the wells as indicated. On day 3 of the cultures, FasL (50×10^{-9} g/ml) or antibody to Fas (50×10^{-9} g/ml) was added to triplicate wells as indicated. The cultures were pulsed with [3 H]-TdR during the final 6 h of 4 day cultures.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is based on the discovery that autologous antigen presenting cells (APCs) can be transfected or transduced to express, process, and properly present an antigen to antigen-specific T cells. Moreover, upon proper presentation, the antigen-specific T cells are activated. Activation of the selected class of antigen-specific T cells permits this class to be distinguished from other T cells and for them to be selectively targeted for ablation.

Such antigen-specific T cell activation provides a model system in which drugs and treatments can be screened to identify those which are effective in arresting growth of or eliminating the antigen-specific T cells. Certain drugs and treatments have already

been identified which have such effect, including administration of CTLA4Ig, a fusion protein which blocks the costimulatory factors B7-1 and -2, administration of Fas ligand, and administration of antibody to Fas. Moreover, such therapeutic agents can be supplied to the activated antigen-specific T cells in a variety of ways. For example, in addition
5 to direct administration, cells which express and secrete the agents can be administered. In addition, genes which encode such agents can be supplied to the antigen presenting cells, such that upon interaction of the antigen presenting cells and the antigen-specific T cells, the latter cells can be both activated and ablated. This technique can be used with any auto-immune disease in which the inciting auto-antigen is known and for which the
10 coding sequence is available.

Antigen presenting cells can be withdrawn from an auto-immune disease patient, such as a myasthenia gravis patient according to techniques well known in the art. They can be found in the blood as well as in the bone marrow. In one embodiment of the invention B cells are purified from the blood and used as the preparation of antigen
15 presenting cells.

All or a part of the coding sequence for acetylcholine receptor is transduced or transfected into the APCs. This can be accomplished by any technique known in the art, including using viral vectors or plasmid vectors. The extracellular portion of the α -subunit (comprising amino acids 1-120) is believed to comprise the epitopes to which
20 most AChR-specific T cells respond. Thus this portion is believed to be sufficient as the presented antigen for the antigen presenting cells. Moreover, it is believed that proper processing signals are required for the antigen presenting cell to properly process the antigen and display it on its surface. Such processing is accomplished by the cellular

endosomes. Proper signals on both the N-terminal and C-terminal portion of the protein are believed to be required. These can be supplied, *inter alia*, using the signal and transmembrane and cytoplasmic tail portions from LAMP-1 and LAMP-2 genes. Such signals are known in the art.

5 Transduced or transfected autologous antigen presenting cells are re-introduced to the patient using standard techniques for transfusing blood cells. The consequence of the introduction is that the acetylcholine receptor-specific T cells are activated.

Administration of an antigen-specific T cell-detrimental product can be by a variety of means. The product itself can be directly administered. Alternatively, cells
10 which express and secrete the product can be administered. Another mode is to transduce or transfect the antigen presenting cells with a gene which expresses the detrimental product. Detrimental products which have been found to successfully inactivate or ablate activated antigen-specific T cells include CTLA4Ig, a fusion protein which binds to and blocks costimulatory B7 molecules on APC cells, Fas ligand, and antibodies to Fas itself.
15 Antibodies which block costimulatory B7-1 and -2 molecules can also be used. It is known in the art that expression of Fas ligand by a cell can be suicidal. Thus if Fas ligand-expressing cells are to be used to administer Fas ligand, then a protective molecule such as truncated FADD should be used. These polypeptides are known in the art to protect expressing cells from the pro-apoptotic effects of Fas ligand.

20 Any viruses capable of introducing exogenous desired DNA to the antigen presenting cells can be used. For example, Vaccinia virus vectors can be used for transducing mature antigen presenting cells. Other non-viral techniques can be used, preferably those which are targeted to the proper cell targets, *i.e.*, the antigen presenting

cells. It is preferred that the viruses be attenuated so that they do not replicate. One suitable means for attenuation is treatment with ultraviolet light, although other means as are known in the art may also be used.

5 In particular Vaccinia viruses with antigen have been made and used. These include Vaccinia with influenza hemagglutinin-LAMP1, AchR(α 1-210)-LAMP1, and Sig-AchR(α 1-210)-LAMP1. We have obtained cDNA for Fas ligand from pTK7.5b plasmid. We have made vaccinia viruses with HA-LAMP1 and Fas ligand; AchR(α 1-210) and Fas ligand; and Sig-AChR(α 1-210) and Fas ligand. Truncated FADD (NFD4) was obtained from pIV113. We have made vaccinia viruses with HA-LAMP1 and Fas
10 ligand and truncated FADD; AchR(α 1-210) and Fas ligand and truncated FADD; and Sig-AChR(α 1-210) and Fas ligand and truncated FADD. The Acetylcholine receptor is derived from Torpedo electroplax. LAMP1 is the transmembrane/cytoplasmic tail of LAMP1, which directs the antigen to the endosomal processing compartment. The signal sequence (Sig) is derived from LAMP1 and is necessary to direct the antigen across
15 membranes. The truncated FADD is an amino terminal truncation which is a dominant negative that prevents Fas ligand/Fas mediated apoptosis.

Transduced or transfected antigen presenting cells, according to the invention are *in vitro* preparations into which DNA has been inserted *ex vivo*. Preferably the cells are purified to remove T cells or other cells which are not antigen presenting cells, or other
20 cells which have not been transduced.

The following is provided as exemplification. The scope of the invention is not defined by the scope of the examples only. All references cited are hereby incorporated by reference herein.

EXAMPLES

A line of APCs derived from BALB/c mice has been engineered to process and present the most important AChR epitopes. The A20 B lymphoma cell line has been
5 transfected with a gene construct coding for the extracellular portion of the α subunit of AChR together with signals that direct it to the endosomal processing compartments. These transfected APCs strongly target and stimulate AChR-specific T cells from BALB/c mice. Further, this endogenous APC-driven stimulation has combined with agents that interfere with T cell function. When stimulated in the presence of CTLA4Ig,
10 the T cells are relatively inactivated; when stimulated in the presence of Fas ligand or antibody to Fas they undergo apoptosis and death. Thus genetic engineering of APCs permits targeting the spectrum of T cells specific for the autoantigen AChR, and permits inactivation or elimination of these T cells.

MATERIALS AND METHODS

15 *Animals and reagents*

Female inbred BALB/c mice, 8 - 12 weeks of age, from Charles River Labs (Wilmington, MA) were used in this study. Acetylcholine receptor (TACHR) was purified from the electric organs of *Torpedo californica* (Pacific Biomarine, Venice CA) by affinity chromatography, using α cobra toxin linked to Sepharose 4B beads, as
20 previously described. The CTLA4Ig fusion protein was generously provided by Bristol-Meyers Squibb Pharmaceutical Research Institute (Princeton, NJ). Plasmids with

cDNA for the α subunit of TACHR were a kind gift from Dr. Toni Claudio. The cDNA for mouse LAMP-1 was a gift from Dr. T. August. The B cell lymphoma line A20, derived from BALB/c mice, was purchased from ATCC.

Immunization of mice

5 To produce lymph node cells primed to TACHR (pLNC), BALB/c mice were immunized intradermally with TACHR (50 μ g emulsified in complete Freund's adjuvant), in multiple sites over the low back. Two weeks later, the draining inguinal lymph nodes were removed, and processed into single-cell suspensions as described previously.

10 *Preparation of Short-term T cell Lines*

In order to confirm the antigen responsiveness of the pLNC from which T cell lines would be produced, the responses of pLNC to AChR *in vitro* were first tested as follows: pLNC were cultured in flat-bottomed 96 well microtiter plates (Costar, Cambridge, MA) at a density of 5×10^5 cells/well. Complete culture medium consisted of: RPMI 1640 containing 2 mM l-glutamine, supplemented with 5% fetal bovine serum (FBS, Hyclone Labs, Logan UT), 5×10^{-5} M 2-mercaptoethanol, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, and 1:100 of 100x penicillin-streptomycin-fungizone (BRL, Gaithersburg, MD). Cells were cultured for 4 days in the presence of an optimum stimulating concentration of TACHR (2.5 μ g/ml), and unstimulated cultures were used for subtraction of background responses.

20 Short-term T-cell lines specific for TACHR were produced as described previously. Briefly, pLNC (5×10^6 /ml) were stimulated with TACHR (2.5 μ g/ml) in bulk cultures (100×10^6 pLNC/ 100 mm plastic tissue culture dish in 20ml) for 4 days. The

activated T cells (2×10^5 cells/ml) were expanded in complete medium containing recombinant human IL2 (rhIL2, 100 IU/ml) and 10% FBS for 5-7 days. The resulting population, which consisted primarily of T cells, responded to AChR stimulation only when antigen presenting cells (APCs) were added, but showed negligible ^3H -TdR
5 incorporation in the absence of added APCs (mean cpm of T cell lines without APCs in 5 different experiments = 587 ± 200 ; significantly different from AChR-stimulated T cell lines cultured *with* APCs [$p < 0.005$] see Fig.2).

Cloning and PCR. The construct used for transfection consisted of cDNA for the extracellular sequence of the TACHR α subunit (amino acids 1-210), with the mouse
10 LAMP-1 signal sequence (LAMP-1sig) at its 5' end, and the mouse Lamp-1 transmembrane and cytoplasmic tail (LAMP-1Tm/Cyt) at its 3' end, cloned into a mammalian expression vector, pcDNA3.1+ plasmid (Invitrogen, Carlsbad, CA) carrying neomycin resistance as a selectable marker (Fig.1a). To evaluate the role of the LAMP-1 signal peptide in AChR antigen processing and presentation, a vector without the cDNA
15 for Lamp-1 sig, but with cDNA that coded for TACHR + LAMP-1Tm/Cyt was also prepared. Sequential cloning methods were used, with TACHR α 1-210 first cloned with both adhesive ends (Hind III at the 5'end, and EcoR I at the 3' end); followed by mouse LAMP-1 sig (both ends with Hind III), and finally mouse LAMP-1 Tm/Cyt domains (EcoR I at the 5' end, and Xho I at the 3' end) cloned into this mammalian expression
20 vector. Each of the insert fragments was first amplified by PCR, using related primers as follows:

TACHR alpha1-210aa

5' CAT ATG GAT CCA AGC TTA TGA TTC TGT GCA GTT ATT GGC

3' AGG CCT CGA GAA TTC AAT ACG CTG CAT GAT AAA ATG G

mouse LAMP-1 sig

5' GGG GAA GCT TAT GGC GGC CCC CGG CG

5 3' ATG CAA GCT TTA GAT CCT CAA AGA GTG C

mouse LAMP-1 Tm/Cyt

5' GGG GGA ATT CTT GAT CCC CAT TGC TGT GGG C

3' AAA ACT CGA GCT AGA TGG TCT GAT AGC CGG C

10 PCR amplification of these fragments was carried out using the high fidelity pfu
polymerase, under the following condition: 94°C - 3min for one cycle; then 94°C, 1 min
/ 60°C, 2min / 72°C for 30 cycles; and finally, 72°C for 10min. Fragments were digested
with restriction enzymes, and the DNA was purified using a QIAquick gel extraction kit
(Qiagen, Chatsworth, CA). DNA ligation reactions were carried out as described. The
15 inserts and the orientation of the mouse LAMP-1 sig were confirmed by PCR with related
primers. The sequence of the entire construct was confirmed in the Johns Hopkins
Genetic Core facility by the dideoxy chain termination method.

Transfection and Selection of A20 cells.

A20 B lymphoma cells were obtained from ATCC, and grown in culture. The
critical parameters for transfection by electroporation were determined empirically to be
20 350 volts and 500uF capacitance. A20 cells in log phase were harvested, washed x3 with
cold serum-free medium, and kept on ice for 15min prior to electroporation. For each
electroporation 8 x 10⁶ A20 cells were mixed with 50-100µg of linearized plasmid in 0.8
ml of serum-free RPMI 1640 at 4°C. They were kept on ice for an additional 15 min.,

and incubated at 37°C in 20ml of recovery medium (20% FBS in complete RPMI 1640 medium). Two days later, transfected cells were selected and maintained with 1mg/ml of G418 in RPMI 1640 with 10% FBS. Transcription of the chimeric mRNA in transfected A20 cells was checked by RT-PCR as described elsewhere.

5 *Antigen Presentation: Lymphoproliferation Assay.*

Antigen presenting cells were first irradiated with a ⁶⁰Co gamma irradiator before use. Splenocytes were treated with 1200 rad at a cell concentration of 5x10⁶ / ml in RPMI 1640 with 10% FBS. A20 cells (either wild type [WT] or transfected) were treated with 15,000 rad ().

10 Briefly, 2.5 x 10⁴ or 5 x 10⁴ cells of the short-term T-cell lines were added to each well. The numbers of APCs added were 2-5 x 10⁵ / well for splenocytes; or 200 to 25,000 /well for WT A20 cells or transfected A20 clones. Triplicate cultures for each treatment were incubated for 3 days in flat-bottom 96-well microculture plates at 37°C. The optimal concentration of antigen (2.5µgTACHR/ml) was used for exogenous antigen stimulation. To assess lymphoproliferation, the cultures were pulsed with [³H]-TdR (1uCi/well, 50ul) during the final 6-12hr of a 3-4day culture period. All cultures were harvested on filters (PHD Cell Harvester, Cambridge Technology, Cambridge, MA) for scintillation counting. Radioactivity incorporated by APCs alone, unstimulated T cell line cultures, and T cell lines cultures with added AChR, was counted. and results are expressed as CPM.

15

20

Assay for Killing of Antigen-stimulated T cells by Fas Ligand or Antibody to Fas.

AChR-specific T cells (5 x 10⁴/well) were incubated with irradiated APCs, either control WT A20 cells or A20 cells stably transfected as above (5 x 10⁴/well). AChR (2.5

μg/ml) was added to some of the wells as indicated in Fig.4. On day 3 of the cultures, FasL (50×10^{-9} g/ml, Calbiochem, Cambridge MA), or antibody to Fas (50×10^{-9} g/ml, Pharmingen, Inc., San Diego, CA) was added to triplicate wells as indicated (Fig.4). The cultures were pulsed with [3 H]-TdR during the final 6 h of 4 day cultures. All studies were carried out in triplicate wells. A typical result is shown in Fig.4.

RESULTS

Transcription and Expression of Gene Construct

RT-PCR was performed on total RNA from transfected A20 clones to determine whether stably transfected A20 cells had transcribed the chimeric gene. Using the forward primer for the 5' end of TACHR and the reverse primer for the 3' end of the mouse LAMP-1 Tm/Cyt domain, the presence of the appropriate mRNA (Fig.1b) was demonstrated.

Functional testing was performed to evaluate the antigen presenting ability of transfected A20 clones. The transfected clones stimulated AChR - specific T cell lines vigorously, without the addition of exogenous AChR (Fig.2). Addition of optimal concentrations of AChR to cultures with these transfected clones did not further enhance stimulation, indicating that the stimulating effect of the transfected clones was maximal. Dose response curves indicated that 200 to 1,000 transfected A20 cells maximally stimulated 2.5×10^3 AChR-specific T cells in culture (Fig.2b). By contrast, when WT A20 cells or splenocytes were used as APCs, stimulation of the AChR-specific T cell line occurred only when exogenous TACHR was added to the cultures.

The ability of A20 clones transfected with cDNA for TACHR plus the LAMP-1 Tm/Cyt domain - *but not the signal peptide sequence* - to stimulate AChR-specific T cell

hybridomas or T cell lines was tested. Only background [³H]- TdR incorporation was induced by these transfectants, unless exogenous TAChR was added to the cultures (data not shown). These results indicate that APCs can be modified by genetic engineering to process and present the "autoantigen" AChR, provided that the gene for the antigen as well as the genes for the required peptide sequences to direct it to the processing lysosomal compartments are in place.

To examine the ability of these APCs to be used to *inactivate* - rather than stimulate- the AChR-specific cells, endogenous stimulation of the target T cells by the transfected APCs was combined with simultaneous treatment with CTLA4Ig (to block costimulation). Endogenous stimulation by transfected A20 cells in the presence of 50 µg/ml of CTLA4Ig resulted in 70% inhibition of stimulation (Fig.3), which is consistent with results of previous studies of *in vitro* effects of CTLA4Ig on AChR-specific T cell stimulation.

The ability of Fas ligand (FasL) and antibody to Fas to induce killing of AChR-specific T cells that were stimulated by transfected APCs (Fig.4) was tested. In order to allow the transfected APCs to complete their stimulation of the T cells, and to avoid possible interference with the APCs, FasL or anti-Fas antibody were first added 72 hrs after initiation of the cultures. Antibody to Fas resulted in virtually 100% inhibition of T cell proliferation, and treatment with soluble hFasL produced 70 to >90% inhibition. See Fig. 4. In these experiments, T cells were stimulated equally strongly by transfected A20 cells presenting endogenous antigen and by control WT A20 cells with added exogenous AChR. Stimulation by transfected A20 cells was not significantly enhanced by the addition of exogenous AChR. The key point is that both FasL and anti-Fas

antibody dramatically inhibited T cells that were stimulated either by endogenously or by exogenously presented AChR.

The development of a strategy for specific immunotherapy of autoimmune disease must meet several challenges. Ideally, it should interfere selectively with the pathogenic autoimmune response, without otherwise compromising the remainder of the immune system. Of necessity, it must cope with ongoing immune responses, which are notoriously difficult to suppress, particularly in an antigen-specific manner. The treatment should inactivate or eliminate the lymphocytes that are responsible for the disease process, and its effect should be long-lasting or permanent. Thus far, the goal of specific immunotherapy has remained elusive. A major problem in designing specific immunotherapy is the heterogeneity of the autoreactive lymphocytes, which recognize multiple epitopes of the autoantigen. Thus, in MG, each individual's T cells respond to multiple epitopes of the autoantigen AChR, and there are marked differences in the patterns of epitopes to which different individuals' T cells respond. Even in rodents inbred to have highly restricted MHC Class II expression, there is significant heterogeneity in the AChR-specific T cell repertoires within a given strain, and even more marked differences in the repertoires in different strains.

The present invention is based on the development of a method of targeting the extensive spectrum of T cells that recognize the autoantigen AChR in MG. The principle underlying the approach is to use the individual patient's own APCs to target the AChR-specific T cells, since the APCs naturally interact with the entire spectrum of antigen-specific T cells for that individual. Modifications are made to induce inactivation

or elimination of the targeted T cells, instead of stimulation.

APCs can be engineered to process and present a model autoantigen, and will effectively target the spectrum of T cells related to autoimmune disease. In these experiments the moiety of TACHR to which the majority of T cells respond - *i.e.* - the
5 extracellular 1-210 amino acid sequence of the α subunit - as the antigen was used. Endogenous presentation by transduced APCs was equivalent to presentation of exogenous AChR, in terms of eliciting T cell proliferative responses.

Effective presentation requires not only cDNA for the autoantigen, but also the appropriate signals to direct it to the endosomal processing compartment. Both LAMP-1
10 sig and LAMP-1 Tm/Cyt are required; without either component the antigen is not be efficiently processed and presented. TACHR + LAMP-1 Tm/Cyt (without sig) were tested, and found virtually no stimulation. When LAMP-1 sig was cloned in to the construct, vigorous stimulation occurred, as above. In a previous study, presentation of
influenza hemagglutinin (HA) required the LAMP-1 Tm/Cyt domain to direct it to the
15 endosomal processing compartment. Since the HA molecule carries its own signal sequence, this was apparently sufficient. Thus, it is clear that both components are necessary to direct the endogenously produced protein antigen to the processing endosomal compartment.

The effects of endogenous autoantigen presentation can be modified by
20 immunomodulatory treatments in the same manner as though the antigen were derived from an exogenous source. Two different methods were tested for interfering with stimulated T cells: blockade of the costimulatory signals provided by B71 and B72, using recombinant CTLA4Ig; and activation of the Fas system, by means of FasL or

antibody to Fas.

CTLA4Ig is a soluble fusion protein consisting of the extracellular domain of the CTLA4 receptor (for B7-1 and B7-2), and the Fc portion of human IgG1 (added for solubility []). CTLA4Ig binds with extremely high affinity to the B7 family of ligands on APCs, and blocks them, thereby preventing the delivery of these costimulatory signals to T cells. CTLA4Ig has been shown to prevent and treat certain autoimmune diseases, including EAMG. Because of the potential usefulness of this approach in the treatment of MG, and because of the availability of the gene for CTLA4Ig, it was tested in our system. CTLA4Ig inhibited AChR-specific T cell proliferation by ~70%, which is consistent with previous results *in vitro*. In the present experiments, the inhibitory effect of CTLA4Ig was somewhat greater when using wild type A20 cells with exogenously provided AChR. This is attributable to weaker stimulation from the exogenously provided TACHR. In previous studies the inhibitory effect of CTLA4Ig on proliferation was greater with weaker stimulation (lower antigen concentrations or fewer APCs).

It has been shown that activated T cells express high levels of the Fas receptor molecules on their surface membranes, but resting T cells do not. Interaction with the cross-linking molecules FasL or antibody to Fas, induces apoptosis of the Fas-bearing cells. FasL and antibody to Fas were supplied exogenously. Both reagents were highly effective in inhibiting AChR-specific T cell proliferation, presumably by inducing Fas-mediated apoptosis. In order to test the effects of these agents on the T cells alone, without damaging APC function, FasL or Fas Ab were added on the 3rd day of the cultures, after maximal stimulation had already occurred. [³H] TdR incorporation was decreased by >70 - 90% after FasL treatment, and by virtually 100% after treatment with

anti-Fas antibody.

These results indicate that the methods of treating myasthenia gravis can be utilized for antigen-specific immunotherapy. The goal is to focus the immunotherapeutic effect at the level of the pivotal autoreactive T lymphocytes. In the case of MG (or
5 EAMG), where the antigen is known to be AChR, the pivotal cells are AChR-specific T cells. Since AChR antibody production is T cell dependent, inactivation or elimination of AChR-specific T cells interferes with AChR antibody production without otherwise altering the function of the immune system.

The genes of interest have been transferred by transduction to demonstrate that the
10 autoantigen can be effectively presented so as to target the appropriate antigen-specific T cells. In order to test the principle of using targeting APCs together with immunomodifying reagents, CTLA4Ig, FasL, and anti-Fas antibody, from exogenous sources were supplied. However, a more efficient method of focusing both antigen presentation *and* the modifying reagent(s) is to use a viral vector which can transfer all
15 the necessary genes for both functions.

CLAIMS:

1. A method of activating auto-antigen-specific T cells in an auto-immune disease patient, comprising the steps of:

removing antigen presenting cells (APCs) from an auto-immune disease patient;

transferring into the APCs a gene which encodes all or a portion of an auto-antigen to which the patient's antigen-specific T cells respond; and

reintroducing the APCs into the patient, whereby auto-antigen-specific T cells are activated.

2. The method of claim 1 wherein the gene which encodes all or a portion of auto-antigen further comprises a signal sequence and a transmembrane and cytoplasmic tail sufficient for endosomal processing.

3. The method of claim 1 further comprising the step of:

administering a product which is detrimental to activated T cell proliferation or survival to the patient.

4. The method of claim 3 wherein the product is CTLA4Ig, a fusion protein which binds to and blocks costimulatory B7 molecules on APC cells.

5. The method of claim 3 wherein the product is a cell which expresses and secretes CTLA4Ig.

6. The method of claim 3 wherein the product is Fas ligand.

7. The method of claim 6 wherein the Fas ligand is administered by administration of APC cells which express Fas ligand.

8. The method of claim 6 wherein the APC cells which express Fas ligand also express A truncated form of FADD which protects cells producing the truncated form of FADD from the apoptotic effects of Fas ligand.

9. The method of claim 3 wherein the product is an antibody specific for Fas.

10. The method of claim 9 wherein the antibody specific for Fas is a monoclonal antibody.

11. The method of claim 9 wherein the antibody specific for Fas is a single chain Fv (ScFv) antibody.

12. The method of claim 11 wherein the antibody is administered by administration of APC cells which express the single chain Fv antibody.

13. The method of claim 8 wherein the APC cells which express Fas ligand and a truncated form of FADD are the same cells which express auto-antigen.

5 14. The method of claim 5 wherein the APC cells which express CTLA4Ig are the same cells which express auto-antigen.

15. The method of claim 7 wherein the APC cells which express Fas ligand are the same cells which express auto-antigen.

16. The method of claim 1 wherein the gene is transferred with a virus.

10 17. The method of claim 16 wherein the virus is attenuated.

18. The method of claim 16 wherein the virus is a vaccinia virus.

19. The method of claim 16 wherein the virus is a Moloney Leukemia Virus.

20. The method of claim 16 wherein said virus further encodes a product which is detrimental to activated T cell proliferation or survival.

15 21. The method of claim 20 wherein the product is Fas ligand.

22. The method of claim 20 wherein the product is a single chain Fv which blocks costimulatory B7 molecules.

23. The method of claim 21 wherein the virus further encodes a truncated form of FADD sufficient to protect a cell expressing it from the apoptotic effects of Fas ligand.

20 24. Antigen presenting cells of an auto-immune disease patient which are transduced or transfected to express a first segment of DNA encoding all or a portion of auto-antigen to which the patient's antigen-specific T cells respond, wherein the cells comprise a second segment of DNA encoding a signal peptide 5' to said first segment and a third segment of DNA encoding a transmembrane and cytoplasmic tail 3' to said first segment, whereby the encoded all or a portion of auto-antigen is processed by endosomes.

25 25. The antigen presenting cells of claim 24 which are transduced or transfected to express a protein which is detrimental to activated T cell survival or proliferation.

30 26. The antigen presenting cells of claim 25 wherein the detrimental protein is Fas ligand.

27. The antigen presenting cells of claim 26 which have been transduced to

express a truncated form of FADD sufficient to protect a cell expressing it from the anti-apoptotic effect of Fas ligand.

28. The antigen presenting cells of claim 25 wherein the detrimental protein is a ScFv which blocks costimulatory B7 molecules.

5 29. A virus which infects human APCs and which comprises a first segment which encodes all or a portion comprising an epitope of an auto-antigen to which auto-immune disease patient's antigen-specific T cells respond.

30. The virus of claim 29 which is a vaccinia virus.

31. The virus of claim 29 which is a Moloney leukemia virus.

10 32. The virus of claim 29 further comprising a second segment which encodes a signal peptide 5' to said first segment and a third segment encoding a transmembrane and cytoplasmic tail 3' to said first segment, whereby the encoded all or a portion of auto-antigen is processed by endosomes.

33. The virus of claim 32 further comprising a fourth segment which encodes
15 a product detrimental to proliferation or survival of activated T cells.

34. The virus of claim 33 wherein the product is Fas ligand.

35. The virus of claim 33 wherein the product is a ScFv which blocks costimulatory B7 molecules.

36. The virus of claim 34 further comprising a fifth segment which encodes a
20 portion of FADD which is sufficient to protect a cell expressing Fas ligand from apoptosis.

37. The virus of claim 29 which is attenuated.

38. The method of claim 1 wherein the auto-antigen is extracellular domain of α -subunit of acetylcholine receptor and the auto-immune disease is myasthenia gravis.

25 39. The antigen presenting cells of claim 24 wherein the auto-antigen is extracellular domain of α -subunit of acetylcholine receptor and the auto-immune disease is myasthenia gravis.

40. The virus of claim 29 wherein the auto-antigen is extracellular domain of α -subunit of acetylcholine receptor and the auto-immune disease is myasthenia gravis.




Fig. 1b




Fig 2a)




Fig 2b)






Fig 3



APC	Untransfected A20	Transfected A20
Antigen	-	+
CTLA4IgG	-	-
	+	+

fig 4



APC	Untransfected A20			Transfected A20		
Antigen	-	+	+	-	+	-
hFasL	-	-	+	-	-	+
Anti-mouse Fas	-	-	-	-	-	+

SEQUENCE LISTING

<110> Drachman, Daniel B.

<120> TARGETING ANTIGEN-SPECIFIC T CELLS FOR
SPECIFIC IMMUNOTHERAPY OF AUTOIMMUNE DISEASE

<130> 01107.77737

<150> 60/067547

<151> 1998-12-03

<160> 6

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> designed primer

<400> 1

catatggatc caagcttatg attctgtgca gttattggc

39

<210> 2

<211> 37

<212> DNA

<213> Artificial Sequence

<400> 2

aggcctcgag aattcaatac gctgcatgat aaaatgg

37

<210> 3

<211> 26

<212> DNA

<213> Artificial Sequence

<400> 3

ggggaagctt atggcggccc ccggcg

26

<210> 4

<211> 28

<212> DNA

<213> Artificial Sequence

<400> 4

atgcaagctt tagatcctca aagagtgc

28

<210> 5

<211> 31

<212> DNA

<213> Artificial Sequence

<400> 5

gggggaattc ttgatcccca ttgctgtggg c

31

<210> 6

<211> 31

<212> DNA

<213> Artificial Sequence

<400> 6

aaaactcgag ctagatgggc tgatagccgg c

31



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/86, 15/12, A61K 48/00, C12N 5/10	A3	(11) International Publication Number: WO 99/29883 (43) International Publication Date: 17 June 1999 (17.06.99)
(21) International Application Number: PCT/US98/25575 (22) International Filing Date: 3 December 1998 (03.12.98) (30) Priority Data: 60/067,547 3 December 1997 (03.12.97) US (71) Applicant: THE JOHNS HOPKINS UNIVERSITY (US/US); Suite 2-100, 2024 E Monument Street, Baltimore, MD 21205 (US). (72) Inventor: DRACHMAN, Daniel, B.; The Johns Hopkins University, Suite 2-100, 2024 E Monument Street, Baltimore, MD 21205 (US). (74) Agents: KAGAN, Sarah, A. et al.; Banner & Witcoff, Ltd., 11th floor, 1001 G Street, N.W., Washington, DC 20001-4597 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 26 August 1999 (26.08.99)
(54) Title: TARGETING ANTIGEN-SPECIFIC T CELLS FOR SPECIFIC IMMUNOTHERAPY OF AUTOIMMUNE DISEASE (57) Abstract <p>Antigen-specific T cells are stimulated to proliferate by activation with properly presented antigen. Targeting a detrimental product to only those cells which are stimulated to proliferate in response to the antigen presentation permits the selective and highly efficient ablation of a key component of the disease symptomology of myasthenia gravis.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KN	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C12N15/86 C12N15/12 A61K48/00 C12N5/10		International Application No. PCT/US 98/25575
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) IPC 6 A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication where appropriate of the relevant passages	Relevant to claim No.
X	DRACHMAN ET AL: "IMMUNOTHERAPY IN NEUROMUSCULAR DISORDERS: CURRENT AND FUTURE STRATEGIES" MUSCLE AND NERVE. vol. 19, 1996. pages 1239-1251. XP002107125	1-5, 14, 16-20, 22, 24, 25, 28-33, 35, 37-40
Y	see page 1245, paragraph 9 - page 1249, paragraph 3	6-13, 15, 21, 23, 26, 27, 34, 36
Y	SHYR-TE JU ET AL: "FAS(CD95)/FASL INTERACTIONS REQUIRED FOR PROGRAMMED CELL DEATH AFTER T-CELL ACTIVATION" NATURE. vol. 373, 2 February 1995. pages 444-448. XP002030470 see the whole document	6-13, 15, 21, 23, 26, 27, 34, 36
-/-		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C		
<input checked="" type="checkbox"/> Patent family members are listed in annex		
Special categories of cited documents		
A* document defining the general state of the art which is not considered to be of particular relevance		
E* earlier document but published on or after the international filing date		
L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)		
O* document referring to an oral disclosure, use, exhibition or other means		
P* document published prior to the international filing date but after than the priority date claimed		
T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention		
X* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone		
Y* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art		
3* document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
24 June 1999		07/07/1999
Name and mailing address of the ISA European Patent Office P.B. 2100 Patentaan 2 NL - 2280 HV Rijswijk Tel (+31-70) 340-2040 Tx (+31-70) 340-2040 Fax (+31-70) 340-3016		Authorized officer Sitch. W

INTEI ATIONAL SEARCH REPORT

International Application No
PCT/US 98/25575

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of documents with indication where appropriate of the relevant passages	Relevant to claim No
Y	WO 96 31603 A (UNIV MICHIGAN :DIXIT VISHVA M (US): ROURKE KAREN O (US)) 10 October 1996 see page 3, line 3 - line 12 see page 45, line 24 - page 46, line 3 ---	8, 13, 23, 27, 36
A	REIM ET AL: "SPECIFIC IMMUNOTHERAPEUTIC STRATEGY FOR MYASTHENIA GRAVIS: TARGETED ANTIGEN-PRESENTING CELLS" JOURNAL OF NEUROIMMUNOLOGY. vol. 41, 1992, pages 61-70, XP002107126 see page 61 see abstract ---	
A	DRACHMAN ET AL: "STRATEGIES FOR TREATMENT OF MYASTHENIA GRAVIS" ANNALS OF THE NEW YORK ACADEMY OF SCIENCES. vol. 681, 1993, pages 515-528, XP002107127 see page 521, paragraph 2 - page 523, paragraph 3 ---	
A	DATABASE MEDLINE FILE SERVER STN KARLSRUHE ABSTRACT 96067660, MCINTOSH K R ET AL: "Immunosuppression and induction of anergy by CTLA4Ig in vitro: effects on cellular and antibody responses of lymphocytes from rats with experimental autoimmune myasthenia gravis." XP002107128 see abstract & CELLULAR IMMUNOLOGY, (1995 NOV) 166 (1) 103-12, JOURNAL CODE: C09, ISSN: 0008-8749.. ---	
A	WO 96 24671 A (CELL GENESYS INC) 15 August 1996 see page 3, line 17 - line 28 see page 11, line 26 - page 35, line 8 -----	

INTERNATIONAL SEARCH REPORT

International application No

PCT/US 98/ 25575

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos
because they relate to subject matter not required to be searched by this Authority namely:
Remark: Although claims 1-23 and 38 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos :
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos :
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant this International Search Report covers all searchable claims
2. ☐ As all searchable claims could be searched without effort justifying an additional fee this Authority did not invite payment of any additional fee
3. ☐ As only some of the required additional search fees were timely paid by the applicant this International Search Report covers only those claims for which fees were paid, specifically claims Nos :
4. ☐ No required additional search fees were timely paid by the applicant. Consequently this International Search Report is restricted to the invention first mentioned in the claims, it is covered by claims Nos

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

relation on patent family members

In tional Application No

PLI/US 98/25575

Parent document cited in search report		Publication date	Patent family members:		Publication date
WO 9631603	A	10-10-1996	AU	5301296 A	23-10-1996
WO 9624671	A	15-08-1996	AU	4776196 A	27-08-1996
			CA	2221571 A	15-08-1996
			EP	0871726 A	21-10-1998